GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Visgeneer Inc (ROCO:4197) » Definitions » EV-to-EBIT

Visgeneer (ROCO:4197) EV-to-EBIT : -21.39 (As of May. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Visgeneer EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Visgeneer's Enterprise Value is NT$346.7 Mil. Visgeneer's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-16.2 Mil. Therefore, Visgeneer's EV-to-EBIT for today is -21.39.

The historical rank and industry rank for Visgeneer's EV-to-EBIT or its related term are showing as below:

ROCO:4197' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.02   Med: 27.93   Max: 1241.01
Current: -21.39

During the past 13 years, the highest EV-to-EBIT of Visgeneer was 1241.01. The lowest was -25.02. And the median was 27.93.

ROCO:4197's EV-to-EBIT is ranked worse than
100% of 423 companies
in the Biotechnology industry
Industry Median: 10.05 vs ROCO:4197: -21.39

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Visgeneer's Enterprise Value for the quarter that ended in Dec. 2023 was NT$348.2 Mil. Visgeneer's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-16.2 Mil. Visgeneer's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4.65%.


Visgeneer EV-to-EBIT Historical Data

The historical data trend for Visgeneer's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Visgeneer EV-to-EBIT Chart

Visgeneer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.89 1,228.37 130.51 24.35 -21.48

Visgeneer Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.51 - 24.35 - -21.48

Competitive Comparison of Visgeneer's EV-to-EBIT

For the Biotechnology subindustry, Visgeneer's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Visgeneer's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Visgeneer's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Visgeneer's EV-to-EBIT falls into.



Visgeneer EV-to-EBIT Calculation

Visgeneer's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=346.675/-16.206
=-21.39

Visgeneer's current Enterprise Value is NT$346.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Visgeneer's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-16.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Visgeneer  (ROCO:4197) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Visgeneer's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-16.206/348.1845
=-4.65 %

Visgeneer's Enterprise Value for the quarter that ended in Dec. 2023 was NT$348.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Visgeneer's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-16.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Visgeneer EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Visgeneer's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Visgeneer (ROCO:4197) Business Description

Traded in Other Exchanges
N/A
Address
Number 335, Sec. 6, Zhonghua Road, Xiangshan District, Hsinchu, TWN, 30094
Visgeneer Inc is a Taiwan based Biotech company involved in developing and, manufacturing biomedical products in the areas of Bacterial Fermentation, Medical Device, Cosmetics/Skin Care, and Cancer Gene identification. Its products include Blood Glucose and Ketone Monitoring System, Ginkgo Biloba series, Peptide-Complex series, Hyaluronic Acid Essence Series and High-Quality Masks among others.

Visgeneer (ROCO:4197) Headlines

No Headlines